PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4080-4089

  Soncini, Chiara ^a   Carpinelli, Patrizia ^a   Gianellini, Laura ^a   Fancelli, Daniele ^a   Vianello, Paola ^a   Rusconi, Luisa ^a   Storici, Paola ^a   Zugnoni, Paola ^a   Pesenti, Enrico ^a   Croci, Valter ^a   Ceruti, Roberta ^a   Giorgini, Maria Laura ^a   Cappella, Paolo ^a   Ballinari, Dario ^a   Sola, Francesco ^a   Varasi, Mario ^a   Bravo, Rodrigo ^a   Moll, Jürgen ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; BIOLOGICAL MARKER; BUB1 RELATED PROTEIN; HISTONE H3; PHA 680632; PHOSPHOTRANSFERASE INHIBITOR; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSGENIC ANIMAL; TUMOR MODEL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HELA CELLS; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; PHENOTYPE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33746080016     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1964     Document Type: Article

References (46)

1. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54.
2. Andrews PD, Knatko E, Moore WJ, et al. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15:672-83.
3. Castro A, Vigneron S, Bernis C, Labbe JC, Prigent C, Lorca T. The D-box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-box sequence of Aurora-A. EMBO Rep 2002;3:1209-14.
4. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 2002;16:2274-85.
5. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C, Lorca T. APC/Fizzy-related targets Aurora-A kinase for proteolysis. EMBO Rep 2002;3:457-62.
6. Honda K, Mihara H, Kato Y, et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000;19:2812-9.
7. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65.
8. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004;166:179-91.
9. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14:29-36.
10. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004;301:60-7.
11. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 2005;5:42-50.
12. Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/lpl1-related protein kinase, AIK3. J Biol Chem 1999;274:7334-40.
13. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63.
14. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64.
15. Li D, Zhu J, Firozi PF, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-7.
16. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999;91:160-2.
17. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-0.
18. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-31.
19. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 2004;25:1631-9.
20. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-71.
21. Tong T, Zhong Y, Kong J, et al. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:7304-10.
22. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
23. Gigoux V, L'Hoste S, Raynaud F, Camonis J, Garbay C. Identification of Aurora kinases as RasGAP Src homology 3 domain-binding proteins. J Biol Chem 2002;277:23742-6.
24. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 2002;21:4491-9.
25. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004;36:55-62.
26. Liu Q, Kaneko S, Yang L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004;279:52175-82.
27. Farruggio DC, Townsley FM, Ruderman JV. Cdc20 associates with the kinase aurora2/Aik. Proc Natl Acad Sci U S A 1999;96:7306-11.
28. Du J, Hannon GJ. The centrosomal kinase Aurora-A/STK15 interacts with a putative tumor suppressor NM23-1. Nucleic Acids Res 2002;30:5465-75.
29. Garber K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst 2005;97:874-6.
30. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36.
31. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94.
32. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80.
33. Gadea BB, Ruderman JV. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell 2005;16:1305-18.
34. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
35. Pevarello P, Brasca MG, Amici R, et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem 2004;47:3367-80.
36. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64:1094-101.
37. Fancelli D, Berta D, Bindi S, et al. Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 2005;48:3080-4.
38. Pascreau G, Arlot-Bonnemains Y, Prigent C. Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 2003;5:369-74.
39. Bayliss R, Sardon T, Vernos I et al. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003;12:851-62.
40. Yang H, Burke T, Dempsey J, et al. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 2005;579:3385-91.
41. Summers MK, Bothos J, Halazonetis TD. The CHFR mitotic checkpoint protein delays cell cycle progression by excluding cyclin B1 from the nucleus. Oncogene 2005;24:2589-98.
42. Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005;37:401-6.
43. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002;22:874-85.
44. Hsu JY, Sun ZW, Li X, et al. Mitotic phosphorylation of histone H3 is governed by lpl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000;102:279-91.
45. Giet R, Glover DM. Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 2001;152:669-82.
46. Choi HS, Choi BY, Cho YY, et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005;65:5818-27.